Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis

[1]  R. Levin.  The puzzle of aspirin and sex. , 2005, The New England journal of medicine.

[2]  J. Manson,et al.  A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women , 2005, The New England journal of medicine.

[3]  C. Hennekens,et al.  An update on aspirin in the primary prevention of cardiovascular disease. , 2003, Archives of internal medicine.

[4]  J. McNeil,et al.  Rationale for a Trial of Low-Dose Aspirin for the Primary Prevention of Major Adverse Cardiovascular Events and Vascular Dementia in the Elderly , 2003, Drugs & aging.

[5]  James F Sallis,et al.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. , 2002, Circulation.

[6]  U. P. S. T. Force,et al.  Measuring Quality: Are We Ready To Compare the Quality of Care among Physician Groups? , 2002, Annals of Internal Medicine.

[7]  S. Hernández-Díaz,et al.  Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. , 2001, British journal of clinical pharmacology.

[8]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[9]  D. Rifkin,et al.  Aspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activity. , 1984, The Journal of clinical investigation.